Despite advances in the treatment of hormone-refractory prostate cancer (HRPC) with
docetaxel chemotherapy as evidenced by the TAX 327 and SWOG 99-16 trials, therapeutic …

5007 Background: Enzalutamide (ENZ), an androgen receptor inhibitor, improved overall
survival (OS) in men with mCRPC who had received prior docetaxel therapy (Scher, N Engl …

CONTEXT: Improved understanding of mechanisms underlying metastatic castration-
resistant prostate cancer (mCRPC) progression has led to the recognition of multiple …

Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen
receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate …

Purpose: Patients with recurrent prostate cancer are commonly treated with androgen
withdrawal therapy (AWT); however, almost all patients eventually progress to castration …

According to recent RCTs, several novel agents and/or combinations exhibit promising
oncologic outcomes. In the first-line setting, OS benefits compared with currently available …

Background Prostate cancer represents the most common cancer in men, leading to 11% of
all male cancer-related deaths [1]. For the last few decades patients with metastatic prostate …

Background ARN-509 is a novel second-generation anti-androgen that binds directly to the
ligand-binding domain of the androgen receptor, impairing nuclear translocation and DNA …

BACKGROUND Prognostic factors associated with clinical outcomes in patients with
metastatic castration‐resistant prostate cancer (mCRPC) treated with a novel androgen …

Despite many recent advances in the therapy for metastatic castration-resistant prostate
cancer (mCRPC), the disease remains incurable, although men suffering from this disease …